Novavax, Inc.
08.07.2013 16:00
---------------------------------------------------------------------------
ROCKVILLE, Md., 2013-07-08 16:00 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX) announced today the approval in Sweden of its
prospectus related to its recommended offer to acquire all outstanding shares
and warrants (warrants series 2005-I and 2005-II) issued by Isconova AB (the
'Offer'), which was first communicated on June 4, 2013.
Prospectus
A prospectus regarding the Offer has been approved and registered by the
Swedish Financial Supervisory Authority (FSA). The prospectus has been
announced today, and the prospectus, together with the United States (U.S.)
prospectus included as part of the registration statement filed by Novavax to
register the shares to be issued in the Offer, are available at Novavax'
webpage (www.novavax.com), at Pareto Ohman AB's webpage (www.paretosec.com),
and at Isconova's webpage (www.isconova.com). The prospectus will also be made
available on the FSA webpage. Acceptance forms will also be made available at
on the Novavax webpage and the Pareto Ohman AB webpage. The prospectus,
together with the U.S. prospectus, an information brochure and pre-printed
acceptance forms will be sent out to directly registered shareholders in
Isconova's share register as of July 4, 2013. Isconova shareholders considering
the Offer should read the information in these documents because they will
contain important information regarding the Offer. The prospectus, the U.S.
prospectus, the information brochure and acceptance forms can also be ordered
from Pareto Ohman AB by phone (+ 46 (0) 8 402 51 32). Isconova shareholders
considering the Offer may obtain copies of all documents filed with the U.S.
Securities and Exchange Commission (SEC) regarding the Offer, free of charge,
at the SEC's website (www.sec.gov).
Timetable
The acceptance period for the Offer commences on July 9, 2013 and ends on July
30, 2013. Payment of consideration is expected to begin on August 9, 2013.
For more information, please contact Pareto Ohman AB, phone (+ 46 (0) 8 402 51
32). This information was made public on July 8, 2013, at 16:00 CET.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines to address a broad range of infectious diseases worldwide.
Using innovative recombinant nanoparticle technology, as well as new and
efficient manufacturing approaches, the company produces vaccine candidates to
combat diseases, with the goal of allowing countries to better prepare for and
more effectively respond to rapidly spreading infections. Novavax is committed
to using its technology platform to create geographic-specific vaccine
solutions and is therefore involved in several international partnerships,
including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences
of Korea and PATH. Together, these organizations support Novavax' worldwide
commercialization strategy and have the global reach to create real and lasting
change in the biopharmaceutical field. Additional information about Novavax is
available on the company's website, www.novavax.com.
John A. Herrmann
VP, General Counsel and Secretary
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
08.07.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Novavax and Isconova to Combine; Novavax' Swedish Prospectus Approved
| Source: EQS Group AG